•  
  •  
  •  
  •  

2026-08-06 15:56:21

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  AurobindoPharma

Research

  • Aurobindo Pharma - Entry into India - a little too late?

Stock Report

  • Aurobindo Pharma signs non-exclusive voluntary license agreement with MSD
  • ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
  • Aurobindo Pharma USA Inc completes acquisition of Lannett Company, Inc
  • Completion of US FDA Inspection at Auroactive Pharma Pvt Ltd
  • Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company
  • Completion of US FDA Pre-Approval Inspection at Eugia Steriles Private Limited
  • Classification of US FDA Inspection at Unit-III of Eugia Pharma Specialities Ltd, Pashamylaram as OAI
  • Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Aurobindo Pharma Inaugurates TheraNym - Pioneering India's Large-Scale Biologics Contract Manufacturing Facility
  • Classification of Unit-I of Eugia Pharma Specialities Ltd, Shameerpet as OAI
  • CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar
  • Aurobindo Pharma receives USFDA Approval for Dextromethorphan Polistirex ExtendedRelease Oral Suspension, 30 mg/5 mL (OTC)
  • Aurobindo Pharma receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • CuraTeQ Biologics announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11
  • CuraTeQ Biologics Pvt Ltd enters into agreement with STADA Arzneimittel AG
  • Classification of Unit-V of Apitoria Pharma Ltd as VAI by the US FDA
  • Eugia Pharma Specialities Ltd receives OAI classification from USFDA for Unit 2
  • Unit-IV of APL Healthcare Ltd classified as VAI by the US FDA
  • Eugia Pharma announces launch of Pomalidomide Capsules in the US
  • Completion of US FDA Inspection at Unit I of Eugia Pharma Specialities Ltd., Shameerpet
  • Eugia Pharma receives USFDA Approval for Everolimus Tablets
  • CuraTeQ Biologics Pvt Ltd and BioFactura Inc, USA to terminate agreement mutually

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025